Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Trial Profile

A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs LHC-165 (Primary) ; Spartalizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Oct 2018 Planned End Date changed from 14 Aug 2019 to 20 Dec 2021.
    • 04 Oct 2018 Planned primary completion date changed from 27 Jun 2019 to 16 Apr 2021.
    • 05 Jun 2018 Planned End Date changed from 7 Feb 2021 to 14 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top